Atlas Trials

Guangzhou Lupeng Pharmaceutical Company LTD.

15 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Guangzhou Lupeng Pharmaceutical Company LTD.

RecordFirmDate
A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies (NCT07609862)Guangzhou Lupeng Pharmaceutical Company LTD.2026-07-14
A Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLL (NCT07609823)Guangzhou Lupeng Pharmaceutical Company LTD.2026-07-14
A Study of Rocbrutinib Combined With R-GemOx in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (NCT07570017)Guangzhou Lupeng Pharmaceutical Company LTD.2026-05-30
A Study Evaluating the Effects of Itraconazole or Rifampin on the Pharmacokinetic Characteristics of Rocbrutinib Tablet (NCT07374224)Guangzhou Lupeng Pharmaceutical Company LTD.2026-03-05
A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma (NCT07377578)Guangzhou Lupeng Pharmaceutical Company LTD.2026-02-05
A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma (NCT07189065)Guangzhou Lupeng Pharmaceutical Company LTD.2025-11-27
Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma (NCT06251180)Guangzhou Lupeng Pharmaceutical Company LTD.2024-04-10
The Mass Balance Study of LP-168 in Healthy Subjects (NCT06126861)Guangzhou Lupeng Pharmaceutical Company LTD.2023-12-25
A Food Effect Study of LP-168 Tablets in Healthy Subjects (NCT05917964)Guangzhou Lupeng Pharmaceutical Company LTD.2023-06-21
A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma (NCT05716087)Guangzhou Lupeng Pharmaceutical Company LTD.2023-02-21
A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML (NCT05641259)Guangzhou Lupeng Pharmaceutical Company LTD.2023-02-14
A Study of LP-168 in Healthy Volunteers (NCT05432713)Guangzhou Lupeng Pharmaceutical Company LTD.2022-05-14
A Study of LP-128 Capsules in Healthy Subjects (NCT05130567)Guangzhou Lupeng Pharmaceutical Company LTD.2021-11-19
A Study of LP-118 in Patients With Advanced Tumors (NCT05025358)Guangzhou Lupeng Pharmaceutical Company LTD.2021-09-08
A Study of LP-168 in Participants With Relapse or Refractory B-Cell Lymphoma (NCT04993690)Guangzhou Lupeng Pharmaceutical Company LTD.2021-07-06

Track Guangzhou Lupeng Pharmaceutical Company LTD. automatically

Every clearance here is in the API, with alerts when new ones post.